Psychophysical aspects of hidradenitis suppurativa

Acta Dermato-Venereologica

Volumn 90, Issue 3, 2010, Pages 264-268

  Matusiak, Łukasz ^a   Bieniek, Andrzej ^a   Szepietowski, Jacek C ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Acne inversa; BDI; DLQI; EQ 5D; FACIT F; Hidradenitis suppurativa; Q LES Q SF; Quality of life

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SUPPURATIVE HIDRADENITIS; WELLBEING;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; DEPRESSION; FATIGUE; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; POLAND; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; STEREOTYPING; YOUNG ADULT;

EID: 77953407746     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0866     Document Type: Article

References (41)

1. Jemec GB, Heidenheim M, Nielsen NH. Hidradenitis suppurativa - characteristics and consequences. Clin Exp Dermatol 1996; 21: 419-423. (Pubitemid 27198665)
2. von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001; 144: 809-813.
3. Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56: 621-623.
4. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006; 154: 726-729.
5. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-628.
6. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572.
7. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
8. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
9. Kurzen H, Kurokawa I, Jemec GB, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, et al. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17: 455-456.
10. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009; 89: 601-603.
11. Poli F, Jemec GB, Revuz J. Clinical presentation. In: Jemec GBE, Revuz J, Leyden JJ, editors. Hidradenitis suppurativa. Heidelberg: Springer, 2006: p. 11-24.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
13. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005; 125: 659-664.
14. Furlanetto LM, Mendlowicz MV, Romildo Bueno J. The validity of the Beck Depression Inventory-Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord 2005; 86: 87-91.
15. Lu Y, Duller P, van der Valk PGM, Evers AWM. Helplessness as predictor of perceived stigmatization in patients with psoriasis and atopic dermatitis. Dermatol Psychosom 2003; 4: 146-150.
16. EuroQoL - A new facility for the measurement of health-related quality of life. The EuroQoL Group. Health Policy 1990; 16: 199-208.
17. Dolan P. Modelling valuations for health states: the effect of duration. Health Policy 1996; 38: 189-203. (Pubitemid 26338161)
18. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
19. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-326. (Pubitemid 23311543)
20. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007; 66: 163-168.
21. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008; 158: 549-557.
22. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
23. Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatol 2007; 215: 123-129.
24. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol 2000; 43: 229-233. (Pubitemid 30625998)
25. Williamson D, Gonzalez M, Finlay AY. Quality of life in patients with hair loss. Br J Dermatol 1997; 137: 47.
26. Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier's disease and Hailey-Hailey disease. Br J Dermatol 1996; 135: 959-963.
27. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol 2008; 22: 87-93.
28. Pacan P, Szepietowski JC, Kiejna A. Stressful life events and depression in patients suffering from psoriasis vulgaris. Dermatol Psychosom 2003; 4: 142-145.
29. Kellermann M, Fekete I, Gesztelyi R, Csiba L, Kollár J, Sikula J, et al. Screening for depressive symptoms in the acute phase of stroke. Gen Hosp Psychiatry 1999; 21: 116-121.
30. van de Kerkhof PC. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol 2004; 151: 663-668.
31. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-518.
32. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007; 5: 70.
33. Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med 2008; 102: 519-536.
34. Darlington AS, Dippel DW, Ribbers GM, van Balen R, Passchier J, Busschbach JJ. Coping strategies as determinants of quality of life in stroke patients: a longitudinal study. Cerebrovasc Dis 2007; 23: 401-407.
35. Sharpies L, Buxton M, Caine N, Cafferty F, Demiris N, Dyer M, et al. Evaluation of the ventricular assist device programme in the UK. Health Technol Assess 2006; 10: 1-119, iii-iv.
36. The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. The Community Pharmacy Medicines Management Project Evaluation Team. Fam Pract 2007; 24: 189-200.
37. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007; 66: 936-939.
38. Viala M, Bhakar AL, de la Loge C, van de Velde H, Esseltine D, Chang M, et al. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. J Clin Epidemiol 2007; 60: 670-679.
39. Hagell P, Höglund A, Reimer J, Eriksson B, Knutsson I, Widner H, et al. Measuring fatigue in Parkinson's disease: a psychometric study of two brief generic fatigue questionnaires. J Pain Symptom Manage 2006; 32: 420-432.
40. Bruera E, El Osta B, Valero V, Driver LC, Pei BL, Shen L, et al. Donepezil for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2007; 25: 3475-3481.
41. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 2073-2078.